Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 15

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
30, 2025 are as follows (in thousands):Operating Leases2025 (excluding the six months ended June 30, 2025)$6,631 202615,765 202715,693 202815,845 202914,484 Thereafter39,150 Total lease payments$107,568 Less: imputed interest(20,824)Present value of operating lease liabilities$86,744 Operating lease liabilities, current$9,669 Operating lease liabilities, noncurrent77,075 Total operating lease liabilities$86,744 The following table summarizes additional information related to operating leases as of June 30, 2025:June 30,2025December 31, 2024Weighted-average remaining lease term7.2 years6.8 yearsWeighted-average discount rate5.9 %5.8 %LitigationThe Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. As of June 30, 2025, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.Bruker (NanoString)Bruker Corporation (“Bruker”) and the Company were previously engaged in litigation in multiple jurisdictions relating to the Company’s Visium products and Bruker’s GeoMx and CosMx products. On May 12, 2025, the Company and Bruker resolved all outstanding litigation between the two companies. All claims in the litigation have been dismissed with prejudice.Vizgen  Vizgen, Inc. (“Vizgen”) and the Company were previously engaged in litigation in multiple jurisdictions relating to the Company’s Xenium products and Vizgen’s MERSCOPE products. On February 5, 2025, the Company and Vizgen resolved all outstanding litigation between the two companies. All claims in the litigation have been dismissed with prejudice.ParseOn August 24, 2022, the Company filed suit against Parse Biosciences, Inc. (“Parse”) in the U.S. District Court for the District of Delaware alleging that Parse’s Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the “981 patent”), 10,697,